A variant form of acute promyelocytic leukemia with marked myelofibrosis

International Journal of Hematology

Volumn 74, Issue 3, 2001, Pages 322-326

  Fukuno, Kenji ^a,b   Tsurumi, Hisashi ^b   Yoshikawa, Takeshi ^a   Yamada, Toshiki ^a   Oyama, Masami ^a   Moriwaki, Hisataka ^b  

^a GIFU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Acute promyelocytic leukemia; CD34; HLA DR; Myelofibrosis; Variant form

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; HLA DR ANTIGEN; HLA DR ANTIGENS; MESSENGER RNA; ONCOPROTEIN; PML RARALPHA PROTEIN; PML-RARALPHA PROTEIN; TUMOR PROTEIN;

ADOLESCENT; ARTICLE; CASE REPORT; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; MYELOFIBROSIS; PATHOLOGY; PROMYELOCYTIC LEUKEMIA; REMISSION; SURVIVAL;

ADOLESCENT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE REPORT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DR ANTIGENS; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MYELOFIBROSIS; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; REMISSION INDUCTION; RNA, MESSENGER;

EID: 0035490635     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982068     Document Type: Article

References (25)

1. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43: 185-190.
2. 1. Acta Haematol. 2000;103: 220-223.
3. Lazzarino M, Morra E, Castello A, et al. Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. Br J Haematol. 1986;64:227-240.
4. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol. 1992;48:208-214.
5. Ishibashi M, Hisano S, Kimura N, et al. Clinical evaluation of bone marrow fibrosis in non-Hodgkin's lymphomas [in Japanese, abstract in English]. Rinsho Ketsueki. 1992;33:297-302.
6. Harada M, Akashi K, Hayashi S, et al. Granulocyte colony stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. Int J Hematol. 1997;66:297-301.
7. Gondo H, Harada M, Miyamoto T, et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1997;20:821-826.
8. Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MAS. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981;57:781-787.
9. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
10. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88:4534-4546.
11. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-β in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 1990;75:1540-1548.
12. Johnston JB, Dalai BI, Israels SJ, et al. Deposition of transforming growth factor-β in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-β by leukemic cells. Am J Clin Pathol. 1995;103:574-582.
13. Allouche M, Bayard F, Clamens S, Fillola G, Sie P, Amalric F. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia. 1995;9;77-86.
14. Kimura A, Nakata Y, Hyodo H, Kuramoto A, Satow Y. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br J Haematol. 1994;86:303-307.
15. Islam A, Catovsky D, Goldman JM, Galton DAG. Bone marrow fibre content in acute myeloid leukaemia before and after treatment. J Clin Pathol. 1984;37:1259-1263.
16. Neame PB, Soamboonsrup P, Leber B, et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol. 1997;56:131-142.
17. Scott CS, Patel D, Drexler HG, Master PS, Limbert HJ, Roberts BE. Immunophenotypic and enzymatic studies do not support the concept of mixed monocytic-granulocytic differentiation in acute promyelocytic leukaemia (M3): a study of 44 cases. Br J Haematol. 1989;71:505-509.
18. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and child acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998;102: 1035-1041.
19. Rovelli A, Biondi A, Cantu Rajnoldi A, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol. 1992;10:1413-1418.
20. Aventin A, Mateu R, Martino R, Colomer D, Bordes R. A case of cryptic acute promyelocytic leukemia. Leukemia. 1998;12: 1490-1491.
21. Foley R, Soamboonsrup P, Kouroukis T, et al. PML/RAR α APL with undifferentiated morphology and stem cell immunophenotype. Leukemia. 1998;12:1492-1493.
22. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978-2986.
23. Burnett AK, Goldstone AH, Stevens RM, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700-708.
24. Thomas X, Dombret H, Cordonnier C, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia. 2000;14:1006-1013.
25. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with alltrans retinoic acid and chemotherapy. J Clin Oncol. 1998;16:78-85.